Notts drug development firm swoops for Reading counterpart
Quotient Sciences, the Ruddington drug development services organisation, has bought Pharmaterials, a contract development and manufacturing organisation (CDMO) based in Reading, for an undisclosed sum.
The deal follows the acquisitions of SeaView Research and QS Pharma in February 2017.
Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The business was founded in 2000 and is located in a 48,000 sq ft facility.
Mark Egerton, chief executi... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
